Today we reported Q2 2026 financial results and business updates. Read our press release here: https://lnkd.in/g5Nevw5X
Autolus Therapeutics
Biotechnology
Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer
About us
Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.
- Website
-
http://www.autolus.com
External link for Autolus Therapeutics
- Industry
- Biotechnology
- Company size
- 501-1,000 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
Get directions
Autolus Limited
London, W12 7RZ, GB
-
Get directions
hertfordshire, UK SG1 2FX, GB
Employees at Autolus Therapeutics
Updates
-
We are excited and honored to announce that the Galien Foundation has presented Autolus with the prestigious 2026 Prix Galien UK Award for Best Biotechnology Product. The award reflects the dedication of our teams, whose work is driven every day by a shared commitment to patients. https://lnkd.in/eFgDjZq4
-
-
To mark World MS Day (30 May), we were pleased to host the MS International Federation (MSIF) team earlier this week at our offices in London. MSIF is a global network of MS patient organisations, bringing together people around the world to both improve the quality of life for those affected by MS and to drive progress to end MS. Autolus is proud to collaborate with MSIF as part of our work in patient advocacy to understand the lived experience of people with MS. Join the conversation and find out more at www.worldmsday.org #MyMSDiagnosis #WorldMSDay
-
-
In honor of #WorldLupusDay we are working to #MakeLupusVisible and show support for the millions of people affected by lupus globally. Autolus is proud to partner with Lupus UK, Lupus Foundation of America, Lupus Research Alliance and Lupus and Allied Diseases Association, Inc. to raise awareness and advocate for better care for those living with lupus.
-
-
Celebrating International Women’s Day 2026 – Give To Gain This year marks 115 years of International Women’s Day, a global celebration of progress, empowerment, and collective action. The 2026 theme, “Give To Gain,” is a powerful reminder that generosity, allyship, and collaboration are catalysts for meaningful change. At Autolus, our ERG Xcellerate brought this theme to life by hosting an inspiring panel discussion. Chaired by Miranda Neville, we heard honest, uplifting perspectives from Cintia Piccina, Rubina Patel, and Gina Basman, who shared their experiences on how giving—whether time, mentorship, or opportunity—creates space for everyone to rise. At the heart of Xcellerate is our commitment to: Elevating the potential of women - Strengthening teams and performance through diversity - Building a supportive network for mentorship, learning, and shared growth. When we give, we don’t lose—we multiply. When women thrive, we all rise. Proud to celebrate IWD and proud of the work our Employee Resource Groups do every day to make Autolus a place where every voice can grow, lead, and shine. #IWD2026 #GiveToGain #WomenInSTEM #EquityInAction #Autolus #Xcellerate
-
-
We were honored to support the third Women in CAR T event at the Tandem meeting, alongside Kite Pharma. It was inspiring to hear from so many brilliant women who are driving innovation, mentorship and working towards improved access for CAR T therapy. We look forward to continuing to support this community of women who are advancing transformative therapies and shaping the future of CAR T. #WomenInCART
-
-
Only approximately 2 out of 10 people in the US with some advanced #BloodCancers receive access to CAR T therapy. That’s why we’re proud to join CAR T Vision and support its bold ambition to double the proportion of eligible patients treated with CAR T-cell therapy by 2030. #ItsTimeForCART
-
-
For investors and analysts We are pleased to announce the first patient has been dosed in our Phase 1 BOBCAT trial of obe-cel in patients with progressive multiple sclerosis (PMS). https://lnkd.in/eMDx9s4S
-
-
Tomorrow, September 20, 2025, marks the third annual World ALL Day. This year’s campaign aims to improve understanding of acute lymphoblastic leukemia, provide support to patients and caregivers through the stages of the patient journey, and to unite the community. To learn more about WORLD ALL Day and KNOWALL visit: https://lnkd.in/gBUVsq9A